Valneva (NASDAQ:VALN) Shares Gap Up – Still a Buy?

Valneva SE (NASDAQ:VALN) gapped up prior to trading on Thursday . The stock had previously closed at $6.73, but opened at $7.06. Valneva shares last traded at $7.15, with a volume of 6,867 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Valneva in a report on Friday, February 28th.

Valneva Stock Performance

The stock has a market capitalization of $585.89 million, a PE ratio of -55.46 and a beta of 1.93. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average of $6.24 and a 200-day moving average of $5.60.

Valneva (NASDAQ:VALN) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Equities analysts anticipate that Valneva SE will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Valneva stock. ABC Arbitrage SA purchased a new stake in Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.